Published: 08.02.2019
References:
- Kompendium — lekarstvennyie preparatyi (2018) GAVISCON (GAVISCON®) (https://compendium.com.ua/info/170935/gaviskon/).
- Skripnik I.M., Maslova G.S. (2010) Gastroezofagealna reflyuksna hvoroba I vagItnIst. Nov. med. farmats., 323 um — lekarstvennyie preparatyi (2018) (http://www.mif-ua.com/archive/article/12451).
- Uspenskiy Yu.P., Baryishnikova N.V., Pahomova I.G. (2009) Klinicheskie perspektivyi ispolzovaniya preparatov na osnove alginovoy kislotyi v lechenii gastroezofagealnoy reflyuksnoy bolezni. RZhGGK (Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii), 2: 79–84.
- Berthon G. (2002) Aluminium speciation in relation to aluminium bioavailability, metabolism and toxicity. Coord. Ghem. Rev., 228(2): 319–341.
- Dent J., Brun J., Fendrick A.M. et al. (1999) An evidence-based appraisal of reflux disease management — the Genval Workshop Report. Gut, 44 (Suppl. 2): S1–S16.
- El-Serag H.B., Graham D.Y., Satia J.A., Rabeneck L. (2005) Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am. J. Gastroenterol., 100(6): 1243–1250.
- Gill S.K., O’Brien L., Einarson T.R., Koren G. (2009a) The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am. J. Gastroenterol., 104(6): 1541–1545.
- Gill S.K., O’Brien L., Koren G. (2009b) The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig. Dis. Sci., 54(9): 1835–1838.
- Kaehny W.D., Hegg A.P., Alfrey A.C. (1977) Gastrointestinal absorption of aluminum from aluminum-containing antacids. N. Engl. J. Med., 296(24): 1389–1390.
- Katz P.O., Gerson L.B., Vela M.F. (2013) Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol., 108(3): 308–328.
- Lindow S.W., Regnéll P., Sykes J., Little S. (2003) An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int. J. Clin. Pract., 57(3): 175–179.
- Majithia R., Johnson D.A. (2012) Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. Drugs, 72(2): 171–179.
- Marrero J.M., Goggin P.M., de Caestecker J.S. et al. (1992) Determinants of pregnancy heartburn. Br. J. Obstet. Gynaecol., 99(9): 731–734.
- Naumann C.R., Zelig C., Napolitano P.G., Ko C.W. (2012) Nausea, vomiting, and heartburn in pregnancy: a prospective look at risk, treatment, and outcome. J. Matern. Fetal. Neonatal. Med., 25(8): 1488–1493.
- Olans L.B., Wolf J.L. (1994) Gastroesophageal reflux in pregnancy. Gastrointest. Endosc. Clin. N. Am., 4(4): 699–712.
- Pasternak B., Hviid A. (2010) Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N. Engl. J. Med., 363(22): 2114–2123.
- Rey E., Rodriguez-Artalejo F., Herraiz M.A. et al. (2007) Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am. J. Gastroenterol., 102(11): 2395–2400.
- Richter J.E. (2011) Heartburn, nausea, vomiting during pregnancy. In: Pregnancy in Gastrointestinal disorders. American college of Gastroenterology, 18–25 pp.
- Servey J., Chang J. (2014) Over-the-Counter Medications in Pregnancy. Am. Fam. Physician, 90(8): 548–555.
- Uzan M., Uzan S., Sureau C., Richard-Berthe C. (1988) Heartburn and regurgitation in pregnancy. Efficacy and innocuousness of treatment with Gaviscon suspension. Rev. Fr. Gynecol. Obstet., 83(7–9): 569–572.